| Autor: |
Brookes, Steve, Biessels, Pieter, F. L. Ng, Nancy, Woods, Caroline, N. Bell, David, Adamson, Gord |
| Zdroj: |
Bioconjugate Chemistry; March 2006, Vol. 17 Issue: 2 p530-537, 8p |
| Abstrakt: |
A novel conjugate of human hemoglobin (Hb) and the nucleoside analogue ribavirin (RBV) was synthesized to demonstrate the utility of Hb as a biocompatible drug carrier for improved drug delivery in the treatment of liver disease. RBV is used in combination with interferon for the treatment of hepatitis C, but its side effects can result in dose limitation or discontinuation of treatment. Targeted delivery of RBV may help to prevent or minimize its toxicity. The hemoglobin−ribavirin conjugate (Hb−RBV) was designed to release bioactive drug upon endocytosis by cells and tissues involved in extracellular Hb catabolism and clearance. Ribavirin-5‘-monophosphate (RBV-P) was prepared from RBV and activated as the 5‘-monophosphorimidazolide (RBV-P-Im) for reaction with carbonmonoxyhemoglobin to yield Hb−RBV consisting of multiple RBV drugs covalently attached as physiologically labile phosphoramidates via their 5‘-hydroxyl groups. A molar drug ratio of six to eight RBV molecules per Hb tetramer was obtained with near complete haptoglobin (Hp) binding of the drug modified Hb maintained. The conjugate complex (Hp−KA−RBV) was selectively taken up in vitro by cells that express the hemoglobin−haptoglobin receptor, CD163. Recovered ribavirin enzymatically cleaved from Hb−RBV showed equipotent antiproliferative activity compared to control unconjugated RBV against human HepG2 and mouse AML12 liver cell lines. Based upon the reported high level of Hb uptake in the liver, Hb−RBV may be useful in the treatment of certain liver diseases, as well as inflammatory disorders associated with CD163-positive macrophages. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
